Help us: Donate
Follow us on:
×

Menu

Back

Second Rejuveron Company Transitions into Clinical Stage

Endogena Therapeutics has dosed its first retinitis pigmentosa patient with a new regenerative treatment.

Rejuveron Press ReleaseRejuveron Press Release

Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, is pleased to announce that the first participant has been treated in Endogena Therapeutics’ phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).

See Endogena’s full press release here.

Rejuveron has a near-majority holding in Endogena, an endogenous regenerative therapeutics company, announcing in late 2021 that it had invested a further $20m in Endogena’s $29 million series A financing round, which has enabled it to progress treatments targeting degenerative diseases of the eye.

This is the second program in the Rejuveron pipeline to enter clinical trials and follows the announcement in March that Rejuvenate BioMed, a Belgium-based biomedical company developing novel combination drugs for age-related diseases had commenced its first Phase 1 clinical trial assessing the company’s lead candidate RJx-01 for the treatment of sarcopenia.

Endogena’s EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can hence potentially preserve or restore visual function. This gene-independent treatment approach has significant advantages in RP, which has multiple genetic causes. EA-2353 has been granted orphan drug designation by the U.S. Food and Drug Administration in May 2021.

For more information on the clinical trials, please visit www.clinicaltrials.gov (Reference: NCT05392751).

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Rejuvenation Startup Summit 2024: May 10-11 in Berlin

Berlin, Germany - May, 23, 2023 - The Forever Healthy Foundation is pleased to announce the second edition of the...

The SynBioBeta Conference is Almost Here

  At Oakland Marriott, California May 23-25, the SynBioBeta Global Synthetic Biology Conference is happening. This is a three-day event...

Annoucing the International Longevity Summit in Africa

On August 23-24, the International Longevity Summit is happening in Johannesburg, South Africa. It will be a convergence of global...

Longevity Summit Dublin

The organizers of Longevity Summit Dublin have issued a brief press release encouraging people to come to this August conference....

No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.